Donal P. Fitzpatrick

Comment on: "Strategies for denosumab discontinuation in postmenopausal osteoporosis" by Degboé et al, Joint Bone Spine. 2026;93:105954.

Journal: Joint bone spine

Published: May 24, 2026

The risk of hypocalcaemia after denosumab administration.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: February 06, 2026

Primary hyperparathyroidism presenting as atraumatic bilateral hip fractures: a case report.

Journal: Journal of medical case reports

Published: August 25, 2025

Angiotensin receptor blockers (ARBs) but not angiotensin converting enzyme inhibitors (ACE-Is) are associated with lower osteoclast activity and higher bone mineral density: Results from the TUDA study.

Journal: Bone

Published: July 29, 2025

Early administration of zoledronic acid after hip fracture.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: December 10, 2024

Letter to Editor From McCarroll et al: "Approach to the Patient: Normocalcemic Primary Hyperparathyroidism".

Journal: The Journal of clinical endocrinology and metabolism

Published: November 13, 2024

Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: June 18, 2024

Letter to the Editor From Fitzpatrick et al: "Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than A Single Infusion?"

Journal: The Journal of clinical endocrinology and metabolism

Published: May 25, 2024

Secondary hyperparathyroidism: Predictors and relationship with vitamin D status, bone turnover markers and bone mineral density.

Journal: Bone

Published: January 05, 2024

Falsely elevated parathyroid hormone in a patient with osteoporosis: a case report and review.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: October 30, 2023

Comment on: "Strategies for denosumab discontinuation in postmenopausal osteoporosis" by Degboé et al, Joint Bone Spine. 2026;93:105954.

Comment on: "Strategies for denosumab discontinuation in postmenopausal osteoporosis" by Degboé et al, Joint Bone Spine. 2026;93:105954.

The risk of hypocalcaemia after denosumab administration.

The risk of hypocalcaemia after denosumab administration.

Primary hyperparathyroidism presenting as atraumatic bilateral hip fractures: a case report.

Primary hyperparathyroidism presenting as atraumatic bilateral hip fractures: a case report.

Angiotensin receptor blockers (ARBs) but not angiotensin converting enzyme inhibitors (ACE-Is) are associated with lower osteoclast activity and higher bone mineral density: Results from the TUDA study.

Angiotensin receptor blockers (ARBs) but not angiotensin converting enzyme inhibitors (ACE-Is) are associated with lower osteoclast activity and higher bone mineral density: Results from the TUDA study.

Early administration of zoledronic acid after hip fracture.

Early administration of zoledronic acid after hip fracture.

Letter to Editor From McCarroll et al: "Approach to the Patient: Normocalcemic Primary Hyperparathyroidism".

Letter to Editor From McCarroll et al: "Approach to the Patient: Normocalcemic Primary Hyperparathyroidism".

Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

Letter to the Editor From Fitzpatrick et al: "Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than A Single Infusion?"

Letter to the Editor From Fitzpatrick et al: "Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than A Single Infusion?"

Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review.

Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review.

Postmenopausal Osteoporosis.

Postmenopausal Osteoporosis.

Secondary hyperparathyroidism: Predictors and relationship with vitamin D status, bone turnover markers and bone mineral density.

Secondary hyperparathyroidism: Predictors and relationship with vitamin D status, bone turnover markers and bone mineral density.

Falsely elevated parathyroid hormone in a patient with osteoporosis: a case report and review.

Falsely elevated parathyroid hormone in a patient with osteoporosis: a case report and review.